SE467255B - 3-imidazolylmetyl-4-karbazoloner, 3-imidazolylmetylen-4-karbazoloner och mellanprodukter - Google Patents
3-imidazolylmetyl-4-karbazoloner, 3-imidazolylmetylen-4-karbazoloner och mellanprodukterInfo
- Publication number
- SE467255B SE467255B SE8704746A SE8704746A SE467255B SE 467255 B SE467255 B SE 467255B SE 8704746 A SE8704746 A SE 8704746A SE 8704746 A SE8704746 A SE 8704746A SE 467255 B SE467255 B SE 467255B
- Authority
- SE
- Sweden
- Prior art keywords
- group
- methyl
- formula
- compound
- hydrogen atom
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title description 37
- 150000001875 compounds Chemical class 0.000 claims description 232
- 239000000203 mixture Substances 0.000 claims description 115
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 51
- -1 prop-2-enyl group Chemical group 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
- 125000003342 alkenyl group Chemical group 0.000 claims description 22
- 230000008569 process Effects 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 125000006239 protecting group Chemical group 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 17
- 239000012458 free base Substances 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- ZRIRTEMBXFFOGF-UHFFFAOYSA-N 9-methyl-3-[(5-methyl-1h-imidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound N1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C ZRIRTEMBXFFOGF-UHFFFAOYSA-N 0.000 claims description 14
- 238000007796 conventional method Methods 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 12
- 239000002585 base Substances 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 7
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 6
- 229910052731 fluorine Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 230000003647 oxidation Effects 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- 125000005596 alkyl carboxamido group Chemical group 0.000 claims description 5
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 5
- 230000018044 dehydration Effects 0.000 claims description 5
- 238000006297 dehydration reaction Methods 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- WLMAZCBBISIIGW-UHFFFAOYSA-N 3-[(5-methyl-1h-imidazol-4-yl)methyl]-1,2,3,9-tetrahydrocarbazol-4-one Chemical compound N1C=NC(CC2C(C=3C4=CC=CC=C4NC=3CC2)=O)=C1C WLMAZCBBISIIGW-UHFFFAOYSA-N 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- QOIIRVNVCWTOOB-UHFFFAOYSA-N 6-fluoro-9-methyl-3-[(5-methyl-1h-imidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound N1C=NC(CC2C(C3=C(N(C4=CC=C(F)C=C43)C)CC2)=O)=C1C QOIIRVNVCWTOOB-UHFFFAOYSA-N 0.000 claims description 2
- XPNYUYVXBFVCNG-UHFFFAOYSA-N 9-(cyclopentylmethyl)-3-[(5-methyl-1h-imidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound N1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)CC3CCCC3)CC2)=O)=C1C XPNYUYVXBFVCNG-UHFFFAOYSA-N 0.000 claims description 2
- RQZWYAUHKPTGHP-UHFFFAOYSA-N 9-methyl-3-[(5-methyl-1h-imidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;hydrate;hydrochloride Chemical compound O.Cl.N1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C RQZWYAUHKPTGHP-UHFFFAOYSA-N 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 181
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 159
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 138
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 81
- 239000007787 solid Substances 0.000 description 64
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 61
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 61
- 235000019441 ethanol Nutrition 0.000 description 57
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 239000000725 suspension Substances 0.000 description 48
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 47
- 239000000284 extract Substances 0.000 description 41
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- 238000003818 flash chromatography Methods 0.000 description 35
- 239000003921 oil Substances 0.000 description 35
- 235000019198 oils Nutrition 0.000 description 35
- 239000012299 nitrogen atmosphere Substances 0.000 description 32
- 239000000047 product Substances 0.000 description 32
- 239000004480 active ingredient Substances 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 31
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 25
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- 229960000583 acetic acid Drugs 0.000 description 22
- 239000003826 tablet Substances 0.000 description 22
- 239000002904 solvent Substances 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 239000011976 maleic acid Substances 0.000 description 18
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 18
- 235000017557 sodium bicarbonate Nutrition 0.000 description 18
- 239000010410 layer Substances 0.000 description 17
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 16
- 239000003054 catalyst Substances 0.000 description 15
- 238000002844 melting Methods 0.000 description 15
- 230000008018 melting Effects 0.000 description 15
- 238000004809 thin layer chromatography Methods 0.000 description 15
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 239000006260 foam Substances 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 11
- 229910000104 sodium hydride Inorganic materials 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 239000012312 sodium hydride Substances 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 7
- 229910052783 alkali metal Inorganic materials 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 238000005984 hydrogenation reaction Methods 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000007800 oxidant agent Substances 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 238000004457 water analysis Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 6
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 6
- 229940043279 diisopropylamine Drugs 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 229910003445 palladium oxide Inorganic materials 0.000 description 6
- JQPTYAILLJKUCY-UHFFFAOYSA-N palladium(ii) oxide Chemical compound [O-2].[Pd+2] JQPTYAILLJKUCY-UHFFFAOYSA-N 0.000 description 6
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 5
- HHJUJCWZKJMCLC-UHFFFAOYSA-N 9-methyl-2,3-dihydro-1h-carbazol-4-one Chemical compound C12=CC=CC=C2N(C)C2=C1C(=O)CCC2 HHJUJCWZKJMCLC-UHFFFAOYSA-N 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 238000005804 alkylation reaction Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- VBCXYXZTBYQKQN-UHFFFAOYSA-N 3-methoxy-6-[(5-methyl-1-tritylimidazol-4-yl)methyl]cyclohex-2-en-1-one Chemical compound C1CC(OC)=CC(=O)C1CC1=C(C)N(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=N1 VBCXYXZTBYQKQN-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000003377 acid catalyst Substances 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 4
- 150000008046 alkali metal hydrides Chemical class 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000005002 aryl methyl group Chemical group 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 4
- 229940029284 trichlorofluoromethane Drugs 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- CVSNQZVXFMLQBI-UHFFFAOYSA-N (5-methyl-1-tritylimidazol-4-yl)methanol Chemical compound CC1=C(CO)N=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 CVSNQZVXFMLQBI-UHFFFAOYSA-N 0.000 description 3
- CXMSDKHVTABCQP-UHFFFAOYSA-N 3-[(5-methyl-1-tritylimidazol-4-yl)methyl]-1,2,3,9-tetrahydrocarbazol-4-one Chemical compound CC1=C(CC2C(C=3C4=CC=CC=C4NC=3CC2)=O)N=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 CXMSDKHVTABCQP-UHFFFAOYSA-N 0.000 description 3
- AHHFSTCSFJWTEF-UHFFFAOYSA-N 4-(chloromethyl)-5-methyl-1-tritylimidazole Chemical compound CC1=C(CCl)N=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 AHHFSTCSFJWTEF-UHFFFAOYSA-N 0.000 description 3
- 102000035037 5-HT3 receptors Human genes 0.000 description 3
- 108091005477 5-HT3 receptors Proteins 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 206010021518 Impaired gastric emptying Diseases 0.000 description 3
- 239000002841 Lewis acid Substances 0.000 description 3
- 235000019759 Maize starch Nutrition 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 description 3
- 238000007907 direct compression Methods 0.000 description 3
- 150000002084 enol ethers Chemical class 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 208000001288 gastroparesis Diseases 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 150000007517 lewis acids Chemical class 0.000 description 3
- 150000002688 maleic acid derivatives Chemical class 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- 235000005074 zinc chloride Nutrition 0.000 description 3
- AEVCSZIHWLNESC-BTJKTKAUSA-N (z)-but-2-enedioic acid;9-methyl-3-[(5-methyl-1h-imidazol-4-yl)methyl]-1,2,3,4-tetrahydrocarbazole Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CC2CC3=C(N(C4=CC=CC=C43)C)CC2)=C1C AEVCSZIHWLNESC-BTJKTKAUSA-N 0.000 description 2
- MWOODERJGVWYJE-UHFFFAOYSA-N 1-methyl-1-phenylhydrazine Chemical compound CN(N)C1=CC=CC=C1 MWOODERJGVWYJE-UHFFFAOYSA-N 0.000 description 2
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 2
- LPUNBYLSYMICAQ-UHFFFAOYSA-N 3-(1h-imidazol-5-ylmethylidene)-9-methyl-1,2-dihydrocarbazol-4-one Chemical compound O=C1C=2C3=CC=CC=C3N(C)C=2CCC1=CC1=CNC=N1 LPUNBYLSYMICAQ-UHFFFAOYSA-N 0.000 description 2
- HFIUXKUESYUXTE-UHFFFAOYSA-N 3-[(5-methyl-1-tritylimidazol-4-yl)methyl]-9-prop-2-ynyl-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=C(CC2C(C3=C(N(C4=CC=CC=C43)CC#C)CC2)=O)N=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 HFIUXKUESYUXTE-UHFFFAOYSA-N 0.000 description 2
- OGKLZMVRSPJXKX-UHFFFAOYSA-N 3-[hydroxy-(5-methyl-1-tritylimidazol-4-yl)methyl]-9-methyl-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=C(C(O)C2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)N=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 OGKLZMVRSPJXKX-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- ZXTZEHXUGOFRNU-UHFFFAOYSA-N 7-fluoro-1,2,3,9-tetrahydrocarbazol-4-one Chemical compound N1C2=CC(F)=CC=C2C2=C1CCCC2=O ZXTZEHXUGOFRNU-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 150000001266 acyl halides Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 2
- 229940117975 chromium trioxide Drugs 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- JOPOVCBBYLSVDA-UHFFFAOYSA-N chromium(6+) Chemical compound [Cr+6] JOPOVCBBYLSVDA-UHFFFAOYSA-N 0.000 description 2
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- YTJXGDYAEOTOCG-UHFFFAOYSA-N lithium;di(propan-2-yl)azanide;oxolane Chemical compound [Li+].C1CCOC1.CC(C)[N-]C(C)C YTJXGDYAEOTOCG-UHFFFAOYSA-N 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- HWYLQXPUQUPPNR-UHFFFAOYSA-N n,n,5-trimethyl-4-[(9-methyl-4-oxo-2,3-dihydro-1h-carbazol-3-yl)methyl]imidazole-1-sulfonamide Chemical compound CN(C)S(=O)(=O)N1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C HWYLQXPUQUPPNR-UHFFFAOYSA-N 0.000 description 2
- 230000007433 nerve pathway Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 208000000689 peptic esophagitis Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000004053 quinones Chemical class 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 229940098466 sublingual tablet Drugs 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- SKVGLOFWEJFQKU-UHFFFAOYSA-N (3-fluorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=CC(F)=C1 SKVGLOFWEJFQKU-UHFFFAOYSA-N 0.000 description 1
- TVRMWMXWORBILT-XYOKQWHBSA-N (3e)-6-methoxy-9-methyl-3-[(5-methyl-1h-imidazol-4-yl)methylidene]-1,2-dihydrocarbazol-4-one Chemical compound O=C1C=2C3=CC(OC)=CC=C3N(C)C=2CC\C1=C/C=1N=CNC=1C TVRMWMXWORBILT-XYOKQWHBSA-N 0.000 description 1
- RCHUCBOPDUJIEA-RAXLEYEMSA-N (9z)-5-methyl-9-[(5-methyl-1h-imidazol-4-yl)methylidene]-7,8-dihydro-6h-cyclohepta[b]indol-10-one Chemical compound N1C=NC(\C=C\2C(C3=C(N(C4=CC=CC=C43)C)CCC/2)=O)=C1C RCHUCBOPDUJIEA-RAXLEYEMSA-N 0.000 description 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- PXTRZCSEMBJNHX-IEJMETINSA-N (z)-but-2-enedioic acid;(3e)-9-methyl-3-[(5-methyl-1h-imidazol-4-yl)methylidene]-1,2-dihydrocarbazol-4-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(\C=C/2C(C3=C(N(C4=CC=CC=C43)C)CC\2)=O)=C1C PXTRZCSEMBJNHX-IEJMETINSA-N 0.000 description 1
- KWFPQJCPGCRLTQ-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-(1h-imidazol-5-ylmethyl)-9-methyl-2,3-dihydro-1h-carbazol-4-one Chemical compound OC(=O)\C=C/C(O)=O.O=C1C=2C3=CC=CC=C3N(C)C=2CCC1CC1=CN=CN1 KWFPQJCPGCRLTQ-BTJKTKAUSA-N 0.000 description 1
- OANRDWXISVYJKB-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-[(5-methyl-1h-imidazol-4-yl)methyl]-1,2,3,9-tetrahydrocarbazol-4-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CC2C(C=3C4=CC=CC=C4NC=3CC2)=O)=C1C OANRDWXISVYJKB-BTJKTKAUSA-N 0.000 description 1
- BFIMOQQEBWWZHX-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-[(5-methyl-1h-imidazol-4-yl)methyl]-9-prop-2-enyl-2,3-dihydro-1h-carbazol-4-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)CC=C)CC2)=O)=C1C BFIMOQQEBWWZHX-BTJKTKAUSA-N 0.000 description 1
- VGXSGPYXCCOUDV-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-[(5-methyl-1h-imidazol-4-yl)methyl]-9-prop-2-ynyl-2,3-dihydro-1h-carbazol-4-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)CC#C)CC2)=O)=C1C VGXSGPYXCCOUDV-BTJKTKAUSA-N 0.000 description 1
- CWAKXOJBHOYTOB-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-methyl-2-[(5-methyl-1h-imidazol-4-yl)methyl]-2,3-dihydrocyclopenta[b]indol-1-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)C)C2)=O)=C1C CWAKXOJBHOYTOB-BTJKTKAUSA-N 0.000 description 1
- LIPWBFGJPBGMOR-BTJKTKAUSA-N (z)-but-2-enedioic acid;5-methyl-9-[(5-methyl-1h-imidazol-4-yl)methyl]-6,7,8,9-tetrahydrocyclohepta[b]indol-10-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)C)CCC2)=O)=C1C LIPWBFGJPBGMOR-BTJKTKAUSA-N 0.000 description 1
- LVJRHLXGKXOLAV-BTJKTKAUSA-N (z)-but-2-enedioic acid;6,9-dimethyl-3-[(5-methyl-1h-imidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CC2C(C3=C(N(C4=CC=C(C)C=C43)C)CC2)=O)=C1C LVJRHLXGKXOLAV-BTJKTKAUSA-N 0.000 description 1
- DEIXUFJCUYRKER-BTJKTKAUSA-N (z)-but-2-enedioic acid;6-fluoro-9-methyl-3-[(5-methyl-1h-imidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CC2C(C3=C(N(C4=CC=C(F)C=C43)C)CC2)=O)=C1C DEIXUFJCUYRKER-BTJKTKAUSA-N 0.000 description 1
- IWNLVHFNZRBXPG-BTJKTKAUSA-N (z)-but-2-enedioic acid;6-hydroxy-9-methyl-3-[(5-methyl-1h-imidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CC2C(C3=C(N(C4=CC=C(O)C=C43)C)CC2)=O)=C1C IWNLVHFNZRBXPG-BTJKTKAUSA-N 0.000 description 1
- NHGZDJJCAFXAIJ-BTJKTKAUSA-N (z)-but-2-enedioic acid;9-(cyclopentylmethyl)-3-[(5-methyl-1h-imidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)CC3CCCC3)CC2)=O)=C1C NHGZDJJCAFXAIJ-BTJKTKAUSA-N 0.000 description 1
- KSWXJBZWUIWGCX-BTJKTKAUSA-N (z)-but-2-enedioic acid;9-cyclopentyl-3-[(5-methyl-1h-imidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)C3CCCC3)CC2)=O)=C1C KSWXJBZWUIWGCX-BTJKTKAUSA-N 0.000 description 1
- UNPYSDRDVAXXMN-BTJKTKAUSA-N (z)-but-2-enedioic acid;9-methyl-3-[(5-methyl-1h-imidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C UNPYSDRDVAXXMN-BTJKTKAUSA-N 0.000 description 1
- XSOMWAHDGNTFDZ-BTJKTKAUSA-N (z)-but-2-enedioic acid;methyl 2-[3-[(5-methyl-1h-imidazol-4-yl)methyl]-4-oxo-2,3-dihydro-1h-carbazol-9-yl]acetate Chemical compound OC(=O)\C=C/C(O)=O.O=C1C=2C3=CC=CC=C3N(CC(=O)OC)C=2CCC1CC=1N=CNC=1C XSOMWAHDGNTFDZ-BTJKTKAUSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- DSXKDTZEIWTHRO-UHFFFAOYSA-N 1,2,3,9-tetrahydrocarbazol-4-one Chemical compound N1C2=CC=CC=C2C2=C1CCCC2=O DSXKDTZEIWTHRO-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 229940005561 1,4-benzoquinone Drugs 0.000 description 1
- RCYFNBYVHAIWKG-UHFFFAOYSA-N 1-(4-fluorophenyl)-1-methylhydrazine Chemical compound CN(N)C1=CC=C(F)C=C1 RCYFNBYVHAIWKG-UHFFFAOYSA-N 0.000 description 1
- VUNICAMVTWBGLR-UHFFFAOYSA-N 1-benzylcarbazol-4-one Chemical compound C1(=CC=CC=C1)CC=1C=CC(C2=C3C=CC=CC3=NC=12)=O VUNICAMVTWBGLR-UHFFFAOYSA-N 0.000 description 1
- TUFIMQRAQOQZOS-UHFFFAOYSA-N 1-methyl-1-(4-methylphenyl)hydrazine Chemical compound CN(N)C1=CC=C(C)C=C1 TUFIMQRAQOQZOS-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YQYLLBSWWRWWAY-UHFFFAOYSA-N 1-tritylimidazole-4-carbaldehyde Chemical compound C1=NC(C=O)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 YQYLLBSWWRWWAY-UHFFFAOYSA-N 0.000 description 1
- ZOMATQMEHRJKLO-UHFFFAOYSA-N 1h-imidazol-2-ylmethanol Chemical compound OCC1=NC=CN1 ZOMATQMEHRJKLO-UHFFFAOYSA-N 0.000 description 1
- CMIBUZBMZCBCAT-UHFFFAOYSA-N 2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)OC(C(O)=O)C(C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-UHFFFAOYSA-N 0.000 description 1
- NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- CBUDAABGAQLDTJ-UHFFFAOYSA-N 3-[(5-methyl-1h-imidazol-4-yl)methyl]-9-prop-2-ynyl-2,3-dihydro-1h-carbazol-4-one Chemical compound N1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)CC#C)CC2)=O)=C1C CBUDAABGAQLDTJ-UHFFFAOYSA-N 0.000 description 1
- PWDYCBLQLHUNDY-UHFFFAOYSA-N 3-[(5-methyl-1h-imidazol-4-yl)methylidene]-2,9-dihydro-1h-carbazol-4-one Chemical compound N1C=NC(C=C2C(C=3C4=CC=CC=C4NC=3CC2)=O)=C1C PWDYCBLQLHUNDY-UHFFFAOYSA-N 0.000 description 1
- QCEQRSXWOJLCLT-UHFFFAOYSA-N 3-[[1-(methoxymethyl)-5-methylimidazol-4-yl]methyl]-9-methyl-2,3-dihydro-1h-carbazol-4-one Chemical compound COCN1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C QCEQRSXWOJLCLT-UHFFFAOYSA-N 0.000 description 1
- KPKCCGDLWWZXTC-UHFFFAOYSA-N 3-[[3-(methoxymethyl)-5-methylimidazol-4-yl]methyl]-9-methyl-2,3-dihydro-1h-carbazol-4-one Chemical compound COCN1C=NC(C)=C1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 KPKCCGDLWWZXTC-UHFFFAOYSA-N 0.000 description 1
- JFTPIEHHCQPVCS-UHFFFAOYSA-N 3-methoxycyclohex-2-en-1-one Chemical compound COC1=CC(=O)CCC1 JFTPIEHHCQPVCS-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- ZYWOERDCOZKMQW-UHFFFAOYSA-N 5-methyl-1-tritylimidazole-4-carbaldehyde Chemical compound CC1=C(C=O)N=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 ZYWOERDCOZKMQW-UHFFFAOYSA-N 0.000 description 1
- GLHMAFAXJJECMG-UHFFFAOYSA-N 5-methyl-3,4-dihydro-2h-pyrido[4,3-b]indol-1-one Chemical compound C12=CC=CC=C2N(C)C2=C1C(=O)NCC2 GLHMAFAXJJECMG-UHFFFAOYSA-N 0.000 description 1
- VRYYCCHJXYRXJG-UHFFFAOYSA-N 5-methyl-6,7,8,9-tetrahydrocyclohepta[b]indol-10-one Chemical compound C1CCCC(=O)C2=C1N(C)C1=CC=CC=C12 VRYYCCHJXYRXJG-UHFFFAOYSA-N 0.000 description 1
- DYZLTTDJAPCUEL-UHFFFAOYSA-N 5-methyl-9-[(5-methyl-1h-imidazol-4-yl)methyl]-6,7,8,9-tetrahydrocyclohepta[b]indol-10-one Chemical compound N1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)C)CCC2)=O)=C1C DYZLTTDJAPCUEL-UHFFFAOYSA-N 0.000 description 1
- GDQTWCAGYSBBAH-UHFFFAOYSA-N 6-methoxy-9-methyl-2,3-dihydro-1h-carbazol-4-one Chemical compound C1CCC(=O)C2=C1N(C)C1=CC=C(OC)C=C12 GDQTWCAGYSBBAH-UHFFFAOYSA-N 0.000 description 1
- OXMICSJZRQMLHL-UHFFFAOYSA-N 6-methoxy-9-methyl-3-[(5-methyl-1h-imidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound O=C1C=2C3=CC(OC)=CC=C3N(C)C=2CCC1CC=1N=CNC=1C OXMICSJZRQMLHL-UHFFFAOYSA-N 0.000 description 1
- AXVYKQAZVWAALU-UHFFFAOYSA-N 7-fluoro-9-methyl-2,3-dihydro-1h-carbazol-4-one Chemical compound C12=CC=C(F)C=C2N(C)C2=C1C(=O)CCC2 AXVYKQAZVWAALU-UHFFFAOYSA-N 0.000 description 1
- CHYCUJUUPFKEJB-UHFFFAOYSA-N 7-fluoro-9-methyl-3-[(5-methyl-1h-imidazol-4-yl)methylidene]-1,2-dihydrocarbazol-4-one Chemical compound N1C=NC(C=C2C(C3=C(N(C4=CC(F)=CC=C43)C)CC2)=O)=C1C CHYCUJUUPFKEJB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- RETKIGKCXWRDNY-BTJKTKAUSA-N 9-(benzenesulfonyl)-3-[(5-methyl-1h-imidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)S(=O)(=O)C=3C=CC=CC=3)CC2)=O)=C1C RETKIGKCXWRDNY-BTJKTKAUSA-N 0.000 description 1
- RUBSDEMGGWBVRR-UHFFFAOYSA-N 9-(cyclopentylmethyl)-3-[(5-methyl-1-tritylimidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound N1=CN(C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C(C)=C1CC(C1=O)CCC2=C1C1=CC=CC=C1N2CC1CCCC1 RUBSDEMGGWBVRR-UHFFFAOYSA-N 0.000 description 1
- XXKGCFWKWOUBMC-BTJKTKAUSA-N 9-benzyl-3-[(5-methyl-1h-imidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;(z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.N1C=NC(CC2C(C3=C(N(C4=CC=CC=C43)CC=3C=CC=CC=3)CC2)=O)=C1C XXKGCFWKWOUBMC-BTJKTKAUSA-N 0.000 description 1
- QISOLAMUZCVHLM-UHFFFAOYSA-N 9-methyl-3-[(5-methyl-1-tritylimidazol-4-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=C(CC2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)N=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 QISOLAMUZCVHLM-UHFFFAOYSA-N 0.000 description 1
- JZDGZVLUBOXTDW-UHFFFAOYSA-N 9-methyl-3-[(5-methyl-1h-imidazol-4-yl)methylidene]-1,2-dihydrocarbazol-4-one Chemical compound N1C=NC(C=C2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)=C1C JZDGZVLUBOXTDW-UHFFFAOYSA-N 0.000 description 1
- YFAGMITZLSBKJT-UHFFFAOYSA-N 9-methyl-3-[(5-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=CN=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 YFAGMITZLSBKJT-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- YMYTVSFSLAWNED-BTJKTKAUSA-N C(\C=C/C(=O)O)(=O)O.CN1C2=CC=CC=C2C=2C(C(CCC12)CC1=CN=CN1C)=O Chemical compound C(\C=C/C(=O)O)(=O)O.CN1C2=CC=CC=C2C=2C(C(CCC12)CC1=CN=CN1C)=O YMYTVSFSLAWNED-BTJKTKAUSA-N 0.000 description 1
- JWWLCDACVRXZBJ-UHFFFAOYSA-N C1CCC(O)=CC1=NNC1=CC=CC(F)=C1 Chemical compound C1CCC(O)=CC1=NNC1=CC=CC(F)=C1 JWWLCDACVRXZBJ-UHFFFAOYSA-N 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XWCDCDSDNJVCLO-UHFFFAOYSA-N Chlorofluoromethane Chemical compound FCCl XWCDCDSDNJVCLO-UHFFFAOYSA-N 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- VUYCBBHNGBWOJM-UHFFFAOYSA-N NCOCl Chemical compound NCOCl VUYCBBHNGBWOJM-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- MEZVEFGYMVVJAR-UHFFFAOYSA-N [N].C1(C=CC=C2C3=CC=CC=C3N=C12)=O Chemical group [N].C1(C=CC=C2C3=CC=CC=C3N=C12)=O MEZVEFGYMVVJAR-UHFFFAOYSA-N 0.000 description 1
- GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical group [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
- GOPYZMJAIPBUGX-UHFFFAOYSA-N [O-2].[O-2].[Mn+4] Chemical class [O-2].[O-2].[Mn+4] GOPYZMJAIPBUGX-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- CYKYAADTSNJEHW-UHFFFAOYSA-N benzyl 4-methyl-5-[(9-methyl-4-oxo-2,3-dihydro-1h-carbazol-3-yl)methyl]imidazole-1-carboxylate Chemical compound C1CC(N(C2=CC=CC=C22)C)=C2C(=O)C1CC1=C(C)N=CN1C(=O)OCC1=CC=CC=C1 CYKYAADTSNJEHW-UHFFFAOYSA-N 0.000 description 1
- VYFURMFVPXHRBG-UHFFFAOYSA-N benzyl 5-methyl-4-[(9-methyl-4-oxo-2,3-dihydro-1h-carbazol-3-yl)methyl]imidazole-1-carboxylate Chemical compound CC1=C(CC2C(C3=C(N(C4=CC=CC=C43)C)CC2)=O)N=CN1C(=O)OCC1=CC=CC=C1 VYFURMFVPXHRBG-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- IRLVOMNMSKSKMH-UHFFFAOYSA-N butanedioic acid;[1-methyl-5-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1,2,4-triazol-3-yl]methanol Chemical compound OC(=O)CCC(O)=O.CN1N=C(CO)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1.CN1N=C(CO)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1 IRLVOMNMSKSKMH-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 1
- ITZXULOAYIAYNU-UHFFFAOYSA-N cerium(4+) Chemical compound [Ce+4] ITZXULOAYIAYNU-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- JGDFBJMWFLXCLJ-UHFFFAOYSA-N copper chromite Chemical compound [Cu]=O.[Cu]=O.O=[Cr]O[Cr]=O JGDFBJMWFLXCLJ-UHFFFAOYSA-N 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HJSLFCCWAKVHIW-UHFFFAOYSA-N cyclohexane-1,3-dione Chemical compound O=C1CCCC(=O)C1 HJSLFCCWAKVHIW-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 239000002815 homogeneous catalyst Substances 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229910000103 lithium hydride Inorganic materials 0.000 description 1
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- BQPIGGFYSBELGY-UHFFFAOYSA-N mercury(2+) Chemical class [Hg+2] BQPIGGFYSBELGY-UHFFFAOYSA-N 0.000 description 1
- KPUYPCFZLOQUMB-NBYYMMLRSA-N methanesulfonic acid;(3e)-9-methyl-3-[(5-methyl-1h-imidazol-4-yl)methylidene]-1,2-dihydrocarbazol-4-one Chemical compound CS(O)(=O)=O.N1C=NC(\C=C/2C(C3=C(N(C4=CC=CC=C43)C)CC\2)=O)=C1C KPUYPCFZLOQUMB-NBYYMMLRSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000037047 psychomotor activity Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000005055 short column chromatography Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000002731 stomach secretion inhibitor Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 229960004016 sucrose syrup Drugs 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide pyridine complex Chemical class O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical group [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB868628473A GB8628473D0 (en) | 1986-11-28 | 1986-11-28 | Chemical compounds |
| GB878726537A GB8726537D0 (en) | 1987-11-12 | 1987-11-12 | Tricyclic ketones |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8704746D0 SE8704746D0 (sv) | 1987-11-27 |
| SE8704746L SE8704746L (sv) | 1988-05-29 |
| SE467255B true SE467255B (sv) | 1992-06-22 |
Family
ID=26291603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8704746A SE467255B (sv) | 1986-11-28 | 1987-11-27 | 3-imidazolylmetyl-4-karbazoloner, 3-imidazolylmetylen-4-karbazoloner och mellanprodukter |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US4822881A (cs) |
| AT (1) | AT396933B (cs) |
| AU (1) | AU605805B2 (cs) |
| BE (1) | BE1001004A4 (cs) |
| CA (1) | CA1326032C (cs) |
| CH (1) | CH676120A5 (cs) |
| CZ (1) | CZ404591A3 (cs) |
| DE (1) | DE3740352A1 (cs) |
| DK (1) | DK169675B1 (cs) |
| ES (1) | ES2008360A6 (cs) |
| FI (1) | FI92062C (cs) |
| FR (1) | FR2611366B1 (cs) |
| GB (1) | GB2202530B (cs) |
| GR (1) | GR871809B (cs) |
| HK (1) | HK51591A (cs) |
| IE (1) | IE61510B1 (cs) |
| IL (1) | IL84635A (cs) |
| IT (1) | IT1211936B (cs) |
| NL (1) | NL8702851A (cs) |
| NO (1) | NO172581C (cs) |
| NZ (1) | NZ222725A (cs) |
| PH (1) | PH30436A (cs) |
| SE (1) | SE467255B (cs) |
| SG (1) | SG46591G (cs) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8518742D0 (en) * | 1985-07-24 | 1985-08-29 | Glaxo Group Ltd | Process |
| GB8812002D0 (en) * | 1988-05-20 | 1988-06-22 | Glaxo Group Ltd | Chemical compounds |
| US5202343A (en) * | 1986-11-28 | 1993-04-13 | Glaxo Group Limited | Tricyclic ketones useful as HT3 -receptor antagonists |
| DE3822792C2 (de) * | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
| US5360800A (en) * | 1987-09-03 | 1994-11-01 | Glaxo Group Limited | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives |
| GB8720693D0 (en) * | 1987-09-03 | 1987-10-07 | Glaxo Group Ltd | Chemical compounds |
| US4939144A (en) * | 1987-10-22 | 1990-07-03 | Glaxo Group Limited | Tricyclic ketone derivatives as 5-HT antagonists |
| US5116984A (en) * | 1988-04-07 | 1992-05-26 | Glaxo Group Limited | Imidazole derivatives |
| DK185489A (da) * | 1988-04-22 | 1989-10-23 | Duphar Int Res | Imidazolylmethyl-cycloalkanoebaaindoloner, deres fremstilling og anvendelse |
| EP0339959A3 (en) * | 1988-04-27 | 1991-03-20 | Glaxo Group Limited | Lactam derivatives |
| GB8812636D0 (en) * | 1988-05-27 | 1988-06-29 | Glaxo Group Ltd | Chemical compounds |
| EP0350129A1 (en) * | 1988-07-07 | 1990-01-10 | Duphar International Research B.V | New annelated indoleketones with an imidazolylalkyl substituent |
| HU207078B (en) * | 1988-08-02 | 1993-03-01 | Glaxo Group Ltd | Process for producing lactam derivatives and pharmaceutical compositions comprising such compounds |
| JPH02160786A (ja) * | 1988-08-02 | 1990-06-20 | Glaxo Group Ltd | ラクタム誘導体 |
| JPH02167280A (ja) * | 1988-08-15 | 1990-06-27 | Glaxo Group Ltd | ラクタム誘導体 |
| GB8820650D0 (en) * | 1988-09-01 | 1988-10-05 | Glaxo Group Ltd | Medicaments |
| JPH02180885A (ja) * | 1988-09-01 | 1990-07-13 | Glaxo Group Ltd | ラクタム誘導体 |
| GB8820651D0 (en) * | 1988-09-01 | 1988-10-05 | Glaxo Group Ltd | Medicaments |
| GB8820653D0 (en) * | 1988-09-01 | 1988-10-05 | Glaxo Group Ltd | Medicaments |
| AU627221B2 (en) * | 1988-09-27 | 1992-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Pyridoindole derivatives and processes for preparation thereof |
| GB8823980D0 (en) * | 1988-10-13 | 1988-11-23 | Glaxo Group Ltd | Chemical compounds |
| US5223625A (en) * | 1988-12-22 | 1993-06-29 | Duphar International Research B.V. | Annelated indolo [3,2,-C]lactams |
| GB8904552D0 (en) | 1989-02-28 | 1989-04-12 | Glaxo Group Ltd | Chemical process |
| HU204049B (en) * | 1989-02-28 | 1991-11-28 | Glaxo Group Ltd | Process for producing lactam derivatives and pharmaceutical compositions comprising same |
| GB8904551D0 (en) * | 1989-02-28 | 1989-04-12 | Glaxo Group Ltd | Chemical compounds |
| JPH0669963B2 (ja) | 1989-04-21 | 1994-09-07 | サンド・アクチエンゲゼルシャフト | ５ｈｔ▲下３▼受容体拮抗薬の治療的用途 |
| GB8928208D0 (en) * | 1989-12-13 | 1990-02-14 | Glaxo Group Ltd | Medicaments |
| HU211081B (en) * | 1990-12-18 | 1995-10-30 | Sandoz Ag | Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same |
| KR100368895B1 (ko) * | 2000-03-30 | 2003-01-24 | 하나제약 주식회사 | 1,2,3,9-테트라하이드로-9-메틸-3-[(2-메틸-1ｈ-이미다졸-1-일)메틸]-4ｈ-카바졸-4-온의 제조방법 |
| ES2281646T3 (es) * | 2002-01-18 | 2007-10-01 | Aryx Therapeutics | Antagonistas del receptor 5-ht3 y procedimientos de utilizacion. |
| JP5955767B2 (ja) | 2009-05-20 | 2016-07-20 | インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） | 損傷性前庭障害の処置における使用のためのセロトニン５−ｈｔ３受容体拮抗薬 |
| ES2432618T3 (es) | 2009-05-20 | 2013-12-04 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3740404A (en) * | 1969-05-09 | 1973-06-19 | American Cyanamid Co | Piperidinomethylenedihydrocarbazolones |
| US3634420A (en) * | 1969-05-09 | 1972-01-11 | American Cyanamid Co | 3(morpholinomethyl)-2 3-dihydro-carbazol-4(1h)-ones |
| GB1365296A (en) * | 1970-10-30 | 1974-08-29 | Unilever Ltd | Dentifrice compositions |
| US4176230A (en) * | 1977-08-04 | 1979-11-27 | Hoffmann-La Roche Inc. | 5-(6-Alkylindol-3-ylmethylene)-1,3-dimethyl-2-(methylimino)-4-imidazolidinones |
| IL58592A (en) * | 1978-11-01 | 1982-12-31 | Wellcome Found | 9-(3-(3,5-cis-dimethylpiperazino)propyl)carbazole and salts thereof,their preparation and pharmaceutical composition containing them |
| DK151884C (da) * | 1979-03-07 | 1988-06-13 | Pfizer | Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf |
| US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
| IE57809B1 (en) * | 1984-01-25 | 1993-04-21 | Glaxo Group Ltd | 1,2,3,9-tetrahydro-3-(imidazol-1-ylmethyl)-4h-carbazol-4 one derivatives |
| DE3680123D1 (en) * | 1985-01-23 | 1991-08-14 | Glaxo Group Ltd | Tetrahydrocarbazolonderivate. |
| GB8518741D0 (en) * | 1985-07-24 | 1985-08-29 | Glaxo Group Ltd | Process |
| GB8518745D0 (en) * | 1985-07-24 | 1985-08-29 | Glaxo Group Ltd | Heterocyclic compounds |
| GB8518743D0 (en) * | 1985-07-24 | 1985-08-29 | Glaxo Group Ltd | Heterocyclic compounds |
-
1987
- 1987-11-26 GR GR871809A patent/GR871809B/el unknown
- 1987-11-27 DK DK624887A patent/DK169675B1/da active
- 1987-11-27 CA CA000552963A patent/CA1326032C/en not_active Expired - Fee Related
- 1987-11-27 IE IE323287A patent/IE61510B1/en not_active IP Right Cessation
- 1987-11-27 SE SE8704746A patent/SE467255B/sv not_active IP Right Cessation
- 1987-11-27 NO NO874959A patent/NO172581C/no unknown
- 1987-11-27 BE BE8701353A patent/BE1001004A4/fr not_active IP Right Cessation
- 1987-11-27 FR FR878716488A patent/FR2611366B1/fr not_active Expired - Fee Related
- 1987-11-27 NL NL8702851A patent/NL8702851A/nl not_active Application Discontinuation
- 1987-11-27 DE DE19873740352 patent/DE3740352A1/de not_active Ceased
- 1987-11-27 US US07/126,202 patent/US4822881A/en not_active Expired - Fee Related
- 1987-11-27 AU AU81845/87A patent/AU605805B2/en not_active Ceased
- 1987-11-27 IT IT8748642A patent/IT1211936B/it active
- 1987-11-27 CH CH4614/87A patent/CH676120A5/fr not_active IP Right Cessation
- 1987-11-27 AT AT0312487A patent/AT396933B/de not_active IP Right Cessation
- 1987-11-27 ES ES8703405A patent/ES2008360A6/es not_active Expired
- 1987-11-27 GB GB8727835A patent/GB2202530B/en not_active Expired - Fee Related
- 1987-11-27 IL IL84635A patent/IL84635A/xx not_active IP Right Cessation
- 1987-11-27 NZ NZ222725A patent/NZ222725A/xx unknown
- 1987-11-27 PH PH36132A patent/PH30436A/en unknown
- 1987-11-27 FI FI875235A patent/FI92062C/fi not_active IP Right Cessation
-
1991
- 1991-06-18 SG SG46591A patent/SG46591G/en unknown
- 1991-07-04 HK HK515/91A patent/HK51591A/xx not_active IP Right Cessation
- 1991-12-23 CZ CS914045A patent/CZ404591A3/cs unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE467255B (sv) | 3-imidazolylmetyl-4-karbazoloner, 3-imidazolylmetylen-4-karbazoloner och mellanprodukter | |
| SE460359B (sv) | 3-imidazolylmetyltetrahydrokarbazoloner, foerfarande foer framstaellning av dessa och en farmaceutisk komposition | |
| US4997831A (en) | Lactam derivatives | |
| EP0210840B1 (en) | Substituted imidazolylmethyltetrahydro-carbazolones | |
| US4808581A (en) | Imidazolyl- indolylpropanones as 5-HT3 receptor antagonists | |
| DK169922B1 (da) | Substituerede (imidazol-4-yl)methylpyrido-, og -azepino-, indolonderivater, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende derivaterne | |
| CZ404491A3 (en) | Lactam derivatives | |
| US5045545A (en) | [(Imidazol-4(and 5)-yl)methyl] tetracyclic ketones having 5-HT3 antagonist activity | |
| EP0266899A2 (en) | Indole derivatives | |
| US4859662A (en) | Tetrahydro-imidazolylmethylcarbazolones and analogs thereof for treating 5-HT function disturbances | |
| US5006544A (en) | Imidazole derivatives and pharmaceutical use thereof | |
| EP0307145A1 (en) | Ketone Derivatives | |
| EP0291172B1 (en) | Ketone derivatives | |
| US5360800A (en) | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives | |
| US5008272A (en) | Lactam derivatives | |
| EP0276163B1 (en) | Indole derivatives | |
| EP0317088A1 (en) | Ketone derivatives | |
| US5202343A (en) | Tricyclic ketones useful as HT3 -receptor antagonists | |
| JP2941702B2 (ja) | ５‐ｈｔ３レセプターにおいて５‐ｈｔの作用に拮抗するラクタム誘導体を含む医薬組成物 | |
| HU199142B (en) | Process for producing tricyclic ketones and pharmaceutical compositions comprising same as active ingredient | |
| EP0345956B1 (en) | Tricyclic ketones | |
| JPH01268686A (ja) | 三環式ケトン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8704746-0 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 8704746-0 Format of ref document f/p: F |